BioWorld

Aug. 13, 2003

Lilly Drops Out Of One Program With Emisphere, Stays In Another

Emisphere Technologies Inc. lost a partner for one oral hormone replacement therapy but will continue to work in tandem on another oral hormone program. (BioWorld Today) Read More

FDA Rule That Limits Patent Stacking Set To Go Into Effect

Missing Out On Sunlight, Dietary Calcium, Vitamin D, Some North American Infants Getting Rickets

QLT Raises $150M In Notes Sale, Plans $50M Buyback Of Stock

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 4, 2026.

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

Slate Medicines launches with focus on headache disorders

BioWorld Science

Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...